|
|
| Line 80: |
Line 80: |
| !Clinical Relevance Details/Other Notes | | !Clinical Relevance Details/Other Notes |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> | | |2p |
| 7
| | |gain |
| |<span class="blue-text">EXAMPLE:</span> Loss | | |2p13 |
| |<span class="blue-text">EXAMPLE:</span> | | |REL |
| chr7
| | |P |
| |<span class="blue-text">EXAMPLE:</span> | | |No |
| Unknown
| | |REL amplification promotes NF-κB signaling activation (PMID: 19380639) |
| |<span class="blue-text">EXAMPLE:</span> D, P | |
| |<span class="blue-text">EXAMPLE:</span> No | |
| |<span class="blue-text">EXAMPLE:</span> | |
| Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
| |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> | | |9p |
| 8
| | |Gain |
| |<span class="blue-text">EXAMPLE:</span> Gain | | |9p24.1 |
| |<span class="blue-text">EXAMPLE:</span> | | |CD274 (PD-L1), PDCD1LG2 (PD-L2), JAK2 |
| chr8
| | |T, P |
| |<span class="blue-text">EXAMPLE:</span> | | |Yes (PMID:20628145) |
| Unknown
| | |9p24.1 amplification drives PD-L1/PD-L2 overexpression, relevant for immune checkpoint inhibitor therapy (PMID: 20628145, 27069084) |
| |<span class="blue-text">EXAMPLE:</span> D, P | |
| | | |
| |<span class="blue-text">EXAMPLE:</span> | |
| Common recurrent secondary finding for t(8;21) (add references).
| |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> | | |<span class="blue-text">EXAMPLE:</span> |
